Who are CDT Equity Inc.'s main suppliers?

CDT Equity Inc. (CDT) key suppliers include: INSTITUTIONAL-INVESTOR, NJS-FORESIGHT-BIO-ADVISORY-LLC, THESPROGEN-PC, CHARLES-RIVER, THIRD-PARTIES. View the full supplier network at chainsifter.com/chain/CDT.

Who are CDT Equity Inc.'s major customers?

CDT Equity Inc. (CDT) key customers include: INSTITUTIONAL-INVESTOR, PURCHASER, ANNUAL-REPORT-EMERGING-GROWTH-COMPANY, AZD1656-GLUCOKINASE-ACTIVATOR-CO, CONDUIT-PHARMACEUTICALS-INC and 8 more. View the full customer network at chainsifter.com/chain/CDT.

What sector is CDT Equity Inc. in?

CDT Equity Inc. (CDT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CDT Equity Inc. Supplier List (CDT): 5 Verified Suppliers

5Suppliers

13Customers

3Debt Items

0Related Chains

Source-Backed Evidence Depth

CDT Equity Inc. (CDT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

5Distinct source URLs

12High confidence

0.764Average confidence

2026-09-14Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

CDT Equity Inc. Suppliers

Ticker	Name	Confidence	Evidence
INSTITUTIONAL-INVESTOR	INSTITUTIONAL-INVESTOR	92%	the Company will have the right from time to time at its option to sell to the Purchaser up to $25 million of the Company’s common stock
NJS-FORESIGHT-BIO-ADVISORY-LLC	NJS-FORESIGHT-BIO-ADVISORY-LLC	92%	the Company entered into a Consulting Agreement, dated December 29, 2025 (the “NJS Agreement ”) with NJS Foresight Bio Advisory, LLC (“ NJS ”) pursuant to which NJS agreed to provide advisory and bus…
THESPROGEN-PC	THESPROGEN-PC	92%	the Company entered into a Consulting Agreement, dated December 28, 2025 (the “ Thesprogen Agreement ”) with Thesprogen, PC (“ Thesprogen ”) pursuant to which Thesprogen will evaluate the Company’s r…
CHARLES-RIVER	CHARLES-RIVER	90%	For the year ended December 31, 2025, the Company recognized $0.2 million in research and development expense in the consolidated statement of operations and comprehensive loss related to the Charles…
THIRD-PARTIES	THIRD-PARTIES	80%	We rely and will continue to rely on certain third parties as the sole source of the materials they supply or the finished products they manufacture.

CDT Equity Inc. Customers

Ticker	Name	Confidence	Evidence
INSTITUTIONAL-INVESTOR	INSTITUTIONAL-INVESTOR	92%	On May 15, 2026, CDT Equity Inc. (the “Company”) entered into the second amendment (the “Amendment No. 2”) to that certain directed stock purchase agreement, dated January 16, 2026 (as amended, the “…
PURCHASER	PURCHASER	92%	the Company issued a Senior Secured Convertible Promissory Note with a total principal amount of up to $555,556 (the 'Note')
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY	ANNUAL-REPORT-EMERGING-GROWTH-COMPANY	62%	rsion costs related to interest-bearing convertible promissory notes, partially offset by a $0.1 million increase in loan settlement fees. Liquidity and Capital Resources Management assesses liquidit…
AZD1656-GLUCOKINASE-ACTIVATOR-CO	AZD1656-GLUCOKINASE-ACTIVATOR-CO	62%	– Global Biotechnology, January 2026 6 Manufacturing The Company has a lease agreement for approximately 2,100 square feet of space in Cambridge, England, with a term from March 2024 to January 2027.…
CONDUIT-PHARMACEUTICALS-INC	CONDUIT-PHARMACEUTICALS-INC	62%	The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which will continue to affec…
CONDUIT-PHARMACEUTICALS-LIMITED	CONDUIT-PHARMACEUTICALS-LIMITED	62%	. For the years ended December 31, 2025 and December 31, 2024, the Company incurred interest expense on the Convertible Promissory Note Payable of nil and $ 0.1 million, respectively. August 2024 Nir…
CONDUIT-PHARMACEUTICALS-LTD	CONDUIT-PHARMACEUTICALS-LTD	62%	nduit UK Management Ltd. (United Kingdom) and Conduit Pharmaceuticals, Ltd. (Cayman Islands). The operating results of Conduit Pharmaceuticals, Ltd. are included in the Company’s consolidated financi…
CONDUIT-UK-MANAGEMENT-LIMITED	CONDUIT-UK-MANAGEMENT-LIMITED	62%	– Global Biotechnology, January 2026 6 Manufacturing The Company has a lease agreement for approximately 2,100 square feet of space in Cambridge, England, with a term from March 2024 to January 2027.…
CORVUS-CAPITAL-LIMITED	CORVUS-CAPITAL-LIMITED	62%	hen Topic 270 applies. The amendments add a comprehensive list of interim disclosure requirements currently required by GAAP and a new disclosure principle requiring an entity to disclose events sinc…
MURPHY-CANYON-ACQUISITION-CORP	MURPHY-CANYON-ACQUISITION-CORP	62%	The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which will continue to affec…
SARBORG-LIMITED	SARBORG-LIMITED	62%	nder the second loan had been drawn. On October 9, 2024, the parties amended the loan agreements to extend the maturity date to December 19, 2024 and modify repayment terms to include (i) a £ 60,000 …
STRAND-HANSON-LIMITED	STRAND-HANSON-LIMITED	62%	strength of these depository institutions or investments, the failure or collapse of one or more of these depository institutions or default on these investments could materially adversely affect our…
UK-MANAGEMENT-LTD	UK-MANAGEMENT-LTD	62%	nduit UK Management Ltd. (United Kingdom) and Conduit Pharmaceuticals, Ltd. (Cayman Islands). The operating results of Conduit Pharmaceuticals, Ltd. are included in the Company’s consolidated financi…

CDT Equity Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CDT-DEBT-8564	Warrants outstanding: 1	90%	xbrl warrant detail from xbrl 2025-12-31.
CDT-DEBT	Debt stack $775,000	90%	Market cache reports total debt of $775,000.
CDT-DEBT-8565	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.

CDT Equity Inc. Acquisitions

Acquired Entity	Name	Confidence	Evidence
CDT-ACQ-0001493152-26-007906	CDT Equity Inc. entered into a Securities Purchase Agreement to acquire shares of Sarborg Limite...	85%	CDT Equity Inc. entered into a Securities Purchase Agreement to acquire shares of Sarborg Limited, issuing common stock and pre-funded warrants.

CDT Equity Inc. Ownership

Holder	Name	Confidence	Evidence
CDT-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 1 tracked holders.

CDT Equity Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.

CDT Equity Inc. Supply Chain